A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

NCT06526923 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

COMBINATION_PRODUCT: SP-101 and doxorubicin Cohort 1
COMBINATION_PRODUCT: SP-101 and doxorubicin Cohort 2

Sponsor

Spirovant Sciences, Inc.